Targeting cancer cell survival mechanisms in pancreatic cancer treatment
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer
This study is looking at new ways to treat pancreatic cancer by blocking certain pathways that help the cancer survive, with the hope of finding better treatments that can help patients feel better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11001532 on NIH RePORTER |
What this research studies
This research investigates new treatment strategies for pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its resistance to standard therapies. The approach focuses on inhibiting two key pathways, MEK and autophagy, which cancer cells use to survive. By understanding how these pathways interact and contribute to treatment resistance, the research aims to develop more effective therapies that could improve patient outcomes. The study will involve analyzing patient tumor samples and using advanced models to explore the cellular responses to these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those who have not responded to existing therapies.
Not a fit: Patients with other types of cancer or those whose pancreatic cancer is not characterized by KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting MEK and autophagy pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Olive, Kenneth P. — Columbia University Health Sciences
- Study coordinator: Olive, Kenneth P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.